Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217386 | 0.91 | GLP1R (0.53) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL14217277 | 0.90 | GLP1R (0.57) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL14477502 | 0.90 | GLP1R (0.57) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL14217286 | 0.90 | GLP1R (0.53) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL14217280 | 0.89 | GLP1R (0.58) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL14998098 | 0.87 | GLP1R (0.47) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL14217261 | 0.87 | GLP1R (0.47) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL19069582 | 0.87 | GLP1R (0.56) | GLP1RC3AR1FOLH1 | |
| SCHEMBL21172251 | 0.87 | GLP1R (0.62) | GLP1RC3AR1MEN1KMT2AFOLH1 | |
| SCHEMBL16140676 | 0.87 | GLP1R (0.49) | GLP1RC3AR1FOLH1NOD1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885C3AR1 1771/4885MEN1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.